Machine Learning for Personalized Medicine

Jean-Philippe Vert

MascotNum 2014, ETH Zurich, April 24, 2014

Complexity of life



1 body = 10^{14} cells

1 cell = 6×10^9 ACGT coding for $20,000$ genes

Sequencing revolution



A flood of *omics* data



Interactome

PubMed

Publications



Genome



Transcriptome



Mutations

Structural variations



Phenome



Epigenome

Cancer


NORMAL CELL
FIRST MUTATION
Cell seems normal but is predisposed to proliferate excessively
SECOND MUTATION
Cell begins to proliferate too much but is otherwise normal
THIRD MUTATION
Cell proliferates more rapidly; it also undergoes structural changes
MALIGNANT CELL
FOURTH OR LATER MUTATION
Cell grows uncontrollably and looks obviously deranged

A cancer cell



A cancer cell



A cancer cell



Opportunities



- What is your risk of developing a cancer? (*prevention*)
- After diagnosis and treatment, what is the risk of relapse? (*prognosis*)
- What specific treatment will cure your cancer? (*personalized medicine*)

Outline

Outline

Breast cancer prognosis







Learning with regularization

Given a training set $(x_i, y_i)_{i=1,\dots,n}$ where $x_i \in \mathbb{R}^p$ (typically, $n = 200, p = 20,000$), we estimate a linear predictor

$$f_\beta(x) = \beta^\top x$$

by solving

$$\min_{\beta \in \mathbb{R}^p} R(\beta) + \lambda \Omega(\beta)$$

where:

- $R(\beta)$ is a convex empirical risk, typically

$$R(\beta) = \frac{1}{n} \sum_{i=1}^{n} \ell(\beta^\top x_i, y_i)$$

  for some loss function ℓ (squared error, logistic loss, hinge loss...)
- $\Omega(\beta)$ is a regularization term, typically $\| \beta \|_2$ (ridge regression, SVM...) or $\| \beta \|_1$ (lasso...)

Gene selection, molecular signature

The idea

- We look for a limited set of genes that are sufficient for prediction.
- Selected genes should inform us about the underlying biology



Lack of stability of signatures



Haury et al. (2011)

Gene networks





Gene networks and expression data

Motivation

- Basic biological functions usually involve the coordinated action of several proteins:
  - Formation of protein complexes
  - Activation of metabolic, signalling or regulatory pathways
- Many pathways and protein-protein interactions are already known
- Hypothesis: the weights of the classifier should be “coherent” with respect to this prior knowledge



Graph based penalty

$$f_\beta(x) = \beta^\top x \qquad \min_\beta R(f_\beta) + \lambda\Omega(\beta)$$

Prior hypothesis

Genes near each other on the graph should have similar weigths.

An idea (Rapaport et al., 2007)

$$\Omega(\beta) = \sum_{i\sim j}(\beta_i - \beta_j)^2\,,$$

$$\min_{\beta\in\mathbb{R}^p} R(f_\beta) + \lambda\sum_{i\sim j}(\beta_i - \beta_j)^2\,.$$

Graph based penalty

$$f_\beta(x) = \beta^\top x \qquad \min_\beta R(f_\beta) + \lambda\Omega(\beta)$$

Prior hypothesis

Genes near each other on the graph should have similar weigths.

An idea (Rapaport et al., 2007)

$$\Omega(\beta) = \sum_{i\sim j}(\beta_i - \beta_j)^2 \,,$$

$$\min_{\beta\in\mathbb{R}^p} R(f_\beta) + \lambda \sum_{i\sim j}(\beta_i - \beta_j)^2 \,.$$

Graph Laplacian

Definition

The Laplacian of the graph is the matrix $L = D - A$.



$$L = D - A = \begin{pmatrix} 1 & 0 & -1 & 0 & 0 \\ 0 & 1 & -1 & 0 & 0 \\ -1 & -1 & 3 & -1 & 0 \\ 0 & 0 & -1 & 2 & -1 \\ 0 & 0 & 0 & 1 & 1 \end{pmatrix}$$

Spectral penalty as a kernel

Theorem

The function $f(x) = \beta^\top x$ where β is solution of

$$\min_{\beta \in \mathbb{R}^p} \frac{1}{n} \sum_{i=1}^{n} \ell\left(\beta^\top x_i, y_i\right) + \lambda \sum_{i \sim j} \left(\beta_i - \beta_j\right)^2$$

is equal to $g(x) = \gamma^\top \Phi(x)$ where γ is solution of

$$\min_{\gamma \in \mathbb{R}^p} \frac{1}{n} \sum_{i=1}^{n} \ell\left(\gamma^\top \Phi(x_i), y_i\right) + \lambda \gamma^\top \gamma \,,$$

and where

$$\Phi(x)^\top \Phi(x') = x^\top K_G x'$$

for $K_G = L^*$, the pseudo-inverse of the graph Laplacian.

Example



$$L^* = \begin{pmatrix} 0.88 & -0.12 & 0.08 & -0.32 & -0.52 \\ -0.12 & 0.88 & 0.08 & -0.32 & -0.52 \\ 0.08 & 0.08 & 0.28 & -0.12 & -0.32 \\ -0.32 & -0.32 & -0.12 & 0.48 & 0.28 \\ -0.52 & -0.52 & -0.32 & 0.28 & 1.08 \end{pmatrix}$$

Classifiers



Classifier



a)



b)

Other penalties with kernels

$$\Phi(x)^\top \Phi(x') = x^\top K_G x'$$

with:

- $K_G = (c + L)^{-}1$ leads to

$$\Omega(\beta) = c \sum_{i=1}^{p} \beta_i^2 + \sum_{i \sim j} (\beta_i - \beta_j)^2 \ .$$

- The diffusion kernel:

$$K_G = \exp_M(-2tL) \, .$$

penalizes high frequencies of β in the Fourier domain.

Other penalties without kernels

- Gene selection + Piecewise constant on the graph

$$\Omega(\beta) = \sum_{i \sim j} |\beta_i - \beta_j| + \sum_{i=1}^{p} |\beta_i|$$

- Gene selection + smooth on the graph

$$\Omega(\beta) = \sum_{i \sim j} (\beta_i - \beta_j)^2 + \sum_{i=1}^{p} |\beta_i|$$

Graph lasso







Two solutions

$$\Omega_{intersection}(\beta) = \sum_{i \sim j} \sqrt{\beta_i^2 + \beta_j^2}\,,$$

$$\Omega_{union}(\beta) = \sup_{\alpha \in \mathbb{R}^p : \forall i \sim j, \|\alpha_i^2 + \alpha_j^2\| \leq 1} \alpha^\top \beta\,.$$

Generalization: Group lasso with overlapping groups

$$\Omega^{\mathcal{G}}_{\text{latent}}(w) \triangleq \begin{cases} \min_{v} \sum_{g \in \mathcal{G}} \|v_g\|_2 \\ w = \sum_{g \in \mathcal{G}} v_g \\ \text{supp}(v_g) \subseteq g. \end{cases}$$



Properties

- Resulting support is a *union* of groups in $\mathcal{G}$.
- Possible to select one variable without selecting all the groups containing it.
- Equivalent to group lasso when there is no overlap

Theoretical results

Consistency in group support (Jacob et al., 2009)

- Let $\bar{w}$ be the true parameter vector.
- Assume that there exists a unique decomposition $\bar{v}_g$ such that $\bar{w} = \sum_g \bar{v}_g$ and $\Omega^{\mathcal{G}}_{\text{latent}}(\bar{w}) = \sum \|\bar{v}_g\|_2$.
- Consider the regularized empirical risk minimization problem $L(w) + \lambda \Omega^{\mathcal{G}}_{\text{latent}}(w)$.

Then

- under appropriate mutual incoherence conditions on X,
- as $n \to \infty$,
- with very high probability,

the optimal solution $\hat{w}$ admits a unique decomposition $(\hat{v}_g)_{g \in \mathcal{G}}$ such that

$$\left\{ g \in \mathcal{G} | \hat{v}_g \neq 0 \right\} = \left\{ g \in \mathcal{G} | \bar{v}_g \neq 0 \right\}.$$

Theoretical results

Consistency in group support (Jacob et al., 2009)

- Let $\bar{w}$ be the true parameter vector.
- Assume that there exists a unique decomposition $\bar{v}_g$ such that $\bar{w} = \sum_g \bar{v}_g$ and $\Omega^{\mathcal{G}}_{\text{latent}}(\bar{w}) = \sum \|\bar{v}_g\|_2$.
- Consider the regularized empirical risk minimization problem $L(w) + \lambda \Omega^{\mathcal{G}}_{\text{latent}}(w)$.

Then

- under appropriate mutual incoherence conditions on X,
- as $n \to \infty$,
- with very high probability,

the optimal solution $\hat{w}$ admits a unique decomposition $(\hat{v}_g)_{g \in \mathcal{G}}$ such that

$$\left\{ g \in \mathcal{G} | \hat{v}_g \neq 0 \right\} = \left\{ g \in \mathcal{G} | \bar{v}_g \neq 0 \right\}.$$

Experiments

Synthetic data: overlapping groups

- 10 groups of 10 variables with 2 variables of overlap between two successive groups :$\{1, \ldots, 10\}, \{9, \ldots, 18\}, \ldots, \{73, \ldots, 82\}$.
- Support: union of 4*th* and 5*th* groups.
- Learn from 100 training points.





Frequency of selection of each variable with the lasso (left) and $\Omega^{\mathcal{G}}_{\text{latent}}(.)$ (middle), comparison of the RMSE of both methods (right).

Lasso signature (accuracy 0.61)



Graph Lasso signature (accuracy 0.64)



Outline

Pharmacogenomics / Toxicogenomics



DREAM8 Toxicogenetics challenge



Genotypes from the 1000 genome project
RNASeq from the Geuvadis project

Bilinear regression

- Cell line X, chemical Y, toxicity Z.
- Bilinear regression model:

$$Z = f(X, Y) + b(Y) + \epsilon\,,$$

- Estimation by kernel ridge regression:

$$\min_{f \in \mathcal{H}, b \in \mathbb{R}^p} \sum_{i=1}^{n} \sum_{j=1}^{p} \left(f(x_i, y_j) + b_j - z_{ij} \right)^2 + \lambda \|f\|^2\,,$$

Solving in $O(max(n,p)^3)$

Theorem 1. *Let $Z \in \mathbb{R}^{n\times p}$ be the response matrix, and $K_X \in \mathbb{R}^{n\times n}$ and $K_Y \in \mathbb{R}^{p\times p}$ be the kernel Gram matrices of the n cell lines and p chemicals, with respective eigenvalue decompositions $K_X = U_X D_X U_X^\top$ and $K_Y = U_Y D_Y U_Y^\top$. Let $\gamma = U_X^\top \mathbf{1}_n$ and $S \in \mathbb{R}^{n\times p}$ be defined by $S_{ij} = 1/\left(\lambda + D_X^i D_Y^j\right)$, where D_X^i (resp. D_Y^i) denotes the i-th diagonal term of D_X (resp. D_Y). Then the solution (f^*, b^*) of (2) is given by*

$$b^* = U_Y Diag\left(S^\top \gamma^{\circ 2}\right)^{-1}\left(S^\top \circ \left(U_Y^\top Z^\top U_X\right)\right)\gamma \tag{3}$$

and

$$\forall (x,y) \in \mathcal{X}\times\mathcal{Y}, \quad f^*(x,y) = \sum_{i=1}^{n}\sum_{j=1}^{p} \alpha_{i,j}^* K_X(x_i,x) K_Y(y_i,y)\,, \tag{4}$$

where

$$\alpha^* = U_X\left(S \circ \left(U_X^\top\left(Z - \mathbf{1}_n b^{*\top}\right)U_Y\right)\right)U_Y^\top\,. \tag{5}$$

Kernel Trick

cell line descriptors



drug descriptors

Kernel Trick

cell line descriptors

kernelized →

Kcell





drug descriptors

Kdrug



Kernel Trick



Kernel Trick



cell line descriptors

kernelized →

Kcell



kernel bilinear regression → $\hat{f}$

drug descriptors

Kernel choice?

. descriptors
. data integration
. missing data

Kdrug



Kernel choice

1. $\mathbf{K}_{\text{cell}}$:
   $\Longrightarrow$ 29 cell line kernels tested
   $\Longrightarrow$ 1 kernel that *integrate all information*
   $\Longrightarrow$ deal with missing data
2. $\mathbf{K}_{\text{drug}}$:
   $\Longrightarrow$ 48 drug kernels tested
   $\Longrightarrow$ multi-task kernels

Kernel choice

1. $\mathbf{K}_{\text{cell}}$:
   $\Longrightarrow$ 29 cell line kernels tested
   $\Longrightarrow$ 1 kernel that *integrate all information*
   $\Longrightarrow$ deal with missing data
2. $\mathbf{K}_{\text{drug}}$:
   $\Longrightarrow$ 48 drug kernels tested
   $\Longrightarrow$ multi-task kernels

Cell line data integration

Covariates
. linear kernel



SNPs
. 10 gaussian kernels



RNA-seq
. 10 gaussian kernels



Cell line data integration



Multi-task drug kernels

1. **Dirac**
2. Multi-Task
3. Feature-based
4. Empirical
5. Integrated



independent regression for each drug

Multi-task drug kernels

1. Dirac
2. **Multi-Task**
3. Feature-based
4. Empirical
5. Integrated



sharing information across drugs

Multi-task drug kernels

1. Dirac
2. Multi-Task
3. **Feature-based**
4. Empirical
5. Integrated

Linear kernel and 10 gaussian kernels based on features:

- CDK (160 descriptors) and SIRMS (9272 descriptors)
- Graph kernel for molecules (2D walk kernel)
- Fingerprint of 2D substructures (881 descriptors)
- Ability to bind human proteins (1554 descriptors)

Multi-task drug kernels



Empirical correlation

1. Dirac
2. Multi-Task
3. Feature-based
4. **Empirical**
5. Integrated



Multi-task drug kernels

1. Dirac
2. Multi-Task
3. Feature-based
4. Empirical
5. **Integrated**

Integrated kernel:

- Combine all information on drugs

29x48 kernel combinations: CV results



CI



29x48 kernel combinations: CV results





29x48 kernel combinations: CV results



Kernel on cell lines: CV results



Kernel on drugs: CV results



Final Submission (ranked 2nd)



Empirical kernel on drugs



Integrated kernel on cell lines



Thanks

institutCurie

European Research Council

erc

Inserm

Institut national
de la santé et de la recherche médicale

MINES
ParisTech